A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine...
A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: Karger
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: Karger
Subjects
More information
Scope and Contents
Contents
Objective: Pegylated liposomal doxorubicin (PLD) and capecitabine (CAP) have separately shown significant antitumor activity in a wide range of solid tumors. A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of their combination in patients with refractory solid tumors. Patients...
Alternative Titles
Full title
A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000090494
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000090494
Other Identifiers
ISSN
0030-2414
E-ISSN
1423-0232
DOI
10.1159/000090494
